Ocugen Misses Q2 EPS by 1c
- ByInvesting.com-
Ocugen (NASDAQ:OCGN) reported Q2 EPS of ($0.09), $0.01 worse than the analyst estimate of ($0.08).
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Ocugen, Inc (OCGN)
NASDAQ
Symbol | Exchange | Currency |
|---|
2.560
-0.110(-4.12%)
After Hours
2.550
-0.010(-0.391%)
- Real-time Data
- Volume:4,076,634
- Day's Range:2.490 - 2.700
- 52 wk Range:1.670 - 17.650
OCGN Overview
- Prev. Close
- 2.67
- Day's Range
- 2.49-2.7
- Revenue
- -
- Open
- 2.7
- 52 wk Range
- 1.67-17.65
- EPS
- -0.307
- Volume
- 4,076,634
- Market Cap
- 554.41M
- Dividend (Yield)
- N/A(N/A)
- Average Volume (3m)
- 5,972,896
- P/E Ratio
- -9.12
- Beta
- 4.21
- 1-Year Change
- -64.25%
- Shares Outstanding
- 216,565,916
- Next Earnings Date
- 11 Nov 2022
What is your sentiment on Ocugen?
or
Market is currently closed. Voting is open during market hours.
Ocugen, Inc News
- Pre-Open Stock Movers 05/23: VMware Surges on Possible Broadcom Takeover; Retails Stocks Sick Again on Downgrades (more...)
- ByInvesting.com-
Pre-Open Stock Movers:VMware (NYSE:VMW) 20% HIGHER; Broadcom (NASDAQ:AVGO) is in advanced talks to acquire VMware (VMW), according to various media sources.SIGA Technologies,...
- Ocugen Falls After FDA Declines EUA for Covaxin
- ByInvesting.com-
By Sam BougheddaInvesting.com -- Ocugen, Inc. (NASDAQ:OCGN) dropped Friday after it announced the FDA declined to issue Emergency Use Authorization (EUA) approval for Covaxin,...
Ocugen, Inc Company Profile
Ocugen, Inc Company Profile
Ocugen, Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing vaccine for COVID-19. The Company's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine candidate is focused on developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). It is developing OCU200, a biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.
Read More
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Sell | Strong Sell | Sell |
| Technical Indicators | Sell | Strong Buy | Strong Sell | Strong Sell | Strong Sell |
| Summary | Sell | Neutral | Strong Sell | Strong Sell | Strong Sell |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 450.10 | 453.80 | 429.20 | +2.40 | +0.54% | 608.40K | London | |||
| 595.40 | 601.60 | 586.60 | +2.40 | +0.41% | 5.77M | London | |||
| 1,969.50 | 1,970.50 | 1,938.50 | +27.50 | +1.42% | 1.45M | London | |||
| 589.50 | 591.50 | 581.50 | -2.50 | -0.42% | 614.93K | London | |||
| 162.30 | 162.30 | 160.50 | +1.10 | +0.68% | 2.42M | London | |||
| 3,160.00 | 3,189.00 | 3,154.00 | -3.0 | -0.10% | 644.45K | London | |||
| 1,167.50 | 1,175.00 | 1,165.50 | +2.50 | +0.21% | 4.47M | London | |||
| 338.50 | 342.00 | 337.50 | -3.00 | -0.88% | 470.56K | London | |||
| 161.85 | 162.30 | 157.90 | -4.15 | -2.50% | 5.83M | London | |||
| 498.25 | 498.25 | 484.30 | +11.55 | +2.37% | 37.25M | London | |||
| 540.70 | 543.10 | 532.00 | -4.40 | -0.81% | 33.49M | London | |||
| 121.56 | 122.06 | 120.74 | -0.22 | -0.18% | 76.31M | London | |||
| 2,418.00 | 2,418.00 | 2,372.50 | +29.00 | +1.21% | 1.98M | London | |||
| 4,592.00 | 4,681.00 | 4,570.00 | -35.0 | -0.76% | 415.77K | London | |||
| 52.50 | 52.50 | 52.50 | +7.000 | +15.38% | 1.00M | London |
- 21 Apr 2022, 12:18buy and hold ,end of the year 10 dollar
- 11 Apr 2022, 16:44Buy will go up!!!
- 23 Mar 2022, 22:29insanely cheap stock ,buy time
- 19 Jan 2022, 21:03Don’t invest 👍👍👍
- 21 Dec 2021, 11:25Soon will go up!!!
- 24 Dec 2021, 12:01when?
- 29 Mar 2022, 07:47this stock is suck. I have been followed since last year..very disappointed.
- 15 Dec 2021, 20:45buy buy Santa Santa rally
- 25 Nov 2021, 05:56time to go up
- 09 Nov 2021, 15:50lovely wat a pump. .??
- 04 Nov 2021, 17:22buy here now long see u at 20 soon till December
- 05 Nov 2021, 07:12bro where is your source,
- 04 Nov 2021, 14:35will end up bw 9-10 b4 we see some positives